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Abstract
Aims/hypothesis The blood triacylglycerol level is one of the main determinants of bloodMg2+ concentration in individuals with
type 2 diabetes. Hypomagnesaemia (blood Mg2+ concentration <0.7 mmol/l) has serious consequences as it increases the risk of
developing type 2 diabetes and accelerates progression of the disease. This study aimed to determine the mechanism by which
triacylglycerol levels affect blood Mg2+ concentrations.
Methods Using samples from 285 overweight individuals (BMI >27 kg/m2) who participated in the 300-Obesity study (an
observational cross-sectional cohort study, as part of the Human Functional Genetics Projects), we investigated the association
between serum Mg2+ with laboratory variables, including an extensive lipid profile. In a separate set of studies, hyperlipidaemia
was induced inmice and in healthy humans via an oral lipid load, and bloodMg2+, triacylglycerol and NEFA concentrations were
measured using colourimetric assays. In vitro, NEFAs harvested from albumin were added in increasing concentrations to several
Mg2+-containing solutions to study the direct interaction between Mg2+ and NEFAs.
Results In the cohort of overweight individuals, serum Mg2+ levels were inversely correlated with triacylglycerols incorporated in
large VLDL particles (r = −0.159, p ≤ 0.01). After lipid loading, we observed a postprandial increase in plasma triacylglycerol and
NEFA levels and a reciprocal reduction in blood Mg2+ concentration both in mice (Δ plasma Mg2+ −0.31 mmol/l at 4 h post oral
gavage) and in healthy humans (Δ plasma Mg2+ −0.07 mmol/l at 6 h post lipid intake). Further, in vitro experiments revealed that
the decrease in plasmaMg2+ may be explained by direct binding ofMg2+ to NEFAs. Moreover, Mg2+ was found to bind to albumin
in a NEFA-dependent manner, evidenced by the fact that Mg2+ did not bind to fatty-acid-free albumin. The NEFA-dependent
reduction in the free Mg2+ concentration was not affected by the presence of physiological concentrations of other cations.
Conclusions/interpretation This study shows that elevated NEFA and triacylglycerol levels directly reduce bloodMg2+ levels, in
part explaining the high prevalence of hypomagnesaemia in metabolic disorders. We show that blood NEFA level affects the free
Mg2+ concentration, and therefore, our data challenge how the fractional excretion of Mg2+ is calculated and interpreted in the
clinic.
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Introduction
Hypomagnesaemia (blood Mg2+ concentration <0.7 mmol/l)
is commonly observed in individuals with type 2 diabetes or
the metabolic syndrome [1–3] and can result in general com-
plaints such as fatigue, headache and weakness [4, 5]. Low
oral Mg2+ intake and low blood Mg2+ levels not only increase
the risk of developing type 2 diabetes but also accelerate dis-
ease progression [6–8]. A reduced blood Mg2+ is also associ-
ated with diabetes-related complications, such as cardiovascu-
lar disease and renal failure [9–12].
Blood Mg2+ levels are carefully maintained between 0.7
and 1.1 mmol/l by the interplay between intestine, bone and
kidney [13]. In blood, approximately 27% ofMg2+ is bound to
albumin and 8% is complexed to anions, such as phosphate,
bicarbonate and citrate, leaving 65% as the free, biologically
active form [14]. Although the phenomenon of albumin bind-
ing to Mg2+ has been known for decades, investigations into
the buffering effect of albumin on the regulation of Mg2+
homeostasis has been largely neglected [15].
Blood fatty acid and triacylglycerol levels are largely reg-
ulated by four organs: the intestine, liver, muscle and adipose
tissue. In the postprandial state, the intestine absorbs dietary
lipids as fatty acids, which are re-esterified into triacylglycer-
ols and incorporated into chylomicrons that reach metaboli-
cally active tissues via the circulation [16]. The liver can also
incorporate fatty acids into triacylglycerol and secrete these as
VLDL particles; this process is especially important during
fasting [17]. Skeletal muscle stores fatty acids in the form of
triacylglycerols but also consumes large amounts of fatty
acids during exercise [18]. White adipose tissue also stores
fatty acids as triacylglycerols, which can be released by lipol-
ysis as NEFAs during a state of energy deprivation [19, 20]. In
the blood, these negatively charged NEFAs are bound to car-
rier proteins, predominantly albumin, via non-polar interac-
tions [21]. In physiological conditions, approximately two
NEFA molecules are bound to a single albumin molecule
[22]. However, in a state of hypertriacylglycerolaemia, up to
seven NEFAmolecules are able to bind to albumin, albeit with
sequentially lower binding constants [21, 22].
In metabolic diseases, high blood triacylglycerol concen-
trations are associated with a lower bloodMg2+ concentration,
but the directionality of this correlation remains unclear [1, 23,
24]. Severe hypomagnesaemia in animals leads to increased
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blood triacylglycerol levels, possibly by disrupting the func-
tion of the enzyme lecithin-cholesterol acyltransferase or by
activating lipolysis in adipose tissue [25, 26]. However,
whether triacylglycerols can affect Mg2+ homeostasis has
not yet been investigated.
In this study, we measured serumMg2+ concentrations and
plasma lipoprotein concentrations and composition in a cohort
of overweight individuals, by use of a metabolomics platform
[27]. To further unravel the exact relationship between
hypertriacylglycerolaemia and Mg2+ levels, we combined a
population-based cross-sectional study with in vivo oral lipid
loading in both humans and mice, and carried out subsequent
investigations in vitro.
Methods
300-Obesity cohort Three hundred and two individuals, aged
55–80 years, were enrolled in the 300-Obesity cohort study
(an observational cross-sectional cohort study within the
Human Functional Genetics Projects) at the Radboud univer-
sity medical center between 2014 and 2016 [28]. The study
was carried out in accordance with the Declaration of Helsinki
and all participants provided informed consent. All partici-
pants had a BMI above 27 kg/m2. Individuals with a recent
cardiovascular event (myocardial infarction, transient ischae-
mic attack, stroke <6 months ago), a history of bariatric sur-
gery or bowel resection, inflammatory bowel disease, renal
dysfunction or increased bleeding tendency, or who used oral
or subcutaneous anticoagulant therapy or thrombocyte aggre-
gation inhibitors (other than acetylsalicylic acid and
carbasalate calcium) were excluded. Blood samples were tak-
en in the morning, following an overnight fast. Blood glucose,
triacylglycerols, total cholesterol and HDL-cholesterol were
measured using standard laboratory procedures (Cobas
C8000; Roche Diagnostics, Risch-Rotkreuz, Switzerland).
The HOMA-IR was calculated using the standard formula,
as published by Matthews et al [29]. High-throughput nuclear
magnetic resonance (NMR) metabolomics platform
(Nightingale’s Biomarker Analysis Platform, Nightingale
Health, Helsinki, Finland) [27] was used for the quantification
of 231 lipid and metabolite measures. The metabolites were
measured in a single experiment, set-up for the quantification
of different metabolite groups. In this article we focus on
lipoproteins: total lipid concentrations of 14 lipoprotein sub-
classes, lipoprotein particles sizes, apolipoproteins and cho-
lesterol. The NMR metabolomics platform used in this study
has previously been used in various epidemiological studies
[30, 31]. Details of the NMR-based metabolomics experimen-
tation have been described previously [27]. In the present
study, serum Mg2+ levels were measured in all individuals.
However, 17measurements had substantial duplo errors (large
deviations [≥0.05mmol/l from the average] between duplicate
measurements) and, therefore, only 285 individuals were in-
cluded in the analysis.
Oral gavage of olive oil in wild-type mice This animal study
was approved by the animal ethics board of the Radboud
University Nijmegen (RU DEC 2015-0073) and by the Dutch
Central Commission for Animal Experiments (CCD,
AVD103002015239). Twelve male C57BL6/J mice (Charles
River, Sulzfeld, Germany) were obtained at an age of 9–
10 weeks. Mice were acclimatised for 2 weeks in a
temperature- and light-controlled room, with six mice per cage
(Eurostandard Type III, Tecniplast, Buguggiate, Italy), and were
allowed free access to acidified tap water and standard pellet
chow (Ssniff Spezialdiäten, Soest, Germany). After the acclima-
tisation period, mice received experimental chow containing
18.3% protein (wt/wt), 4.1% crude fat (wt/wt), 25.1% starch
(wt/wt) and 33.6% sugar (wt/wt) (E15000-04; Ssniff
Spezialdiäten). After 2 weeks on the synthetic diet, mice were
fasted overnight, from 21:00 to 09:00 hours, before receiving
200 μl intragastric olive oil (extra virgin; Carbonell, Cordoba,
Spain) via oral gavage. Blood was drawn via tail-bleed, using
chilled sodium-heparin capillary tubes (Praxisdienst, Longuich,
Germany) coated with paraoxon (Sigma, St Louis, MO, USA),
before the gavage (0 h) and at 1, 2, 4, 6 and 8 h post gavage.
The blood was centrifuged at 3000 g and plasma was procured.
Oral gavage of olive oil in a mouse model of diabetes All
procedures for this experiment were conducted in compliance
with the UK Animals Scientific Procedures Act (1986) and
University of Oxford ethical guidelines. Kir6.2-p.Val59Met
mice were generated in our laboratories, as previously pub-
lished [32]. All mice were 12–16 weeks old. Mice were
housed with a maximum of five animals per cage (ventilated),
separated by gender and with ad libitum access to food and
standard pellet chow, in a 12 h light/dark cycle, at 21°C. In
four male and four female C57BL6 mice, expression of a
Kir6.2-p.Val59Met transgene was induced using subcutane-
ous injection of 400 μl tamoxifen (0.02 g/ml corn oil). This
inducible mouse model recapitulates the phenotype of neona-
tal diabetes and these mice develop diabetes due to impaired
insulin secretion [32, 33].
Three days after tamoxifen injection, mice were fasted over-
night from 17:00 to 09:00 hours. Successful induction of the
Kir6.2-p.Val59Met transgene was validated by measuring fasted
blood glucose levels using a StatStrip Xpress glucose meter
(Nova Biomedical, Waltham, MA, USA). One female mouse
did not have elevated fasting glucose levels and was excluded
from subsequent analyses. The remaining mice then underwent
oral gavage and blood sampling using an identical experimental
set up to that described above for C57BL6/J wild-type mice.
BSA and fatty-acid-free BSA solutions BSA and fatty-acid-free
BSA (FF-BSA) (both Sigma Aldrich) were separately
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dissolved at several concentrations in a 1 mmol/l MgCl2 so-
lution (Merck Millipore, Darmstadt, Germany) or a physio-
logical buffer, both set at pH 7.5 by adding NaOH. The phys-
iological buffer contained the following (all from Merck
Millipore unless stated otherwise): 27 mmol/l NaHCO3,
112 mmol/l NaCl, 5 mmol/l KCl, 1 mmol/l MgCl2, 1 mmol/l
Na2HPO4 (VWR International, Radnor, PA, USA) and
2.5 mmol/l CaCl2 dissolved in Milli-Q (Radboud Institute
for Molecular Life Sciences, Nijmegen, the Netherlands).
Increasing NEFA levels in BSA, FBS and MgCl2 solutions To
extract endogenous NEFAs, BSA (0.2 g/ml) dissolved in
Milli-Q was mixed (1:2 vol./vol.) with ice-cold ethanol–
diethyl ether (3:1 vol./vol.). The lipid phase was evaporated
overnight at room temperature. To remove trace amounts of
BSA, the solutionwas centrifuged three times with anAmicon
50 kDa filter (Merck Millipore) for 15 min at 2500 g to clog
the protein in the filter. Extracted NEFAs were added to 250 μl
FBS (Biowest, Nuaillé, France), 1 mmol/l MgCl2, or
0.5 mmol/l BSA in the amounts of 0, 25, 50, 100, 200, 350,
500 and 700 μl. Dilution factors were accounted for when
measuring the concentrations of Mg2+ and NEFA.
Analytical measurements Protein (Pierce, Thermo Scientific,
Waltham, MA, USA), NEFA (WAKO Diagnostics, Delfzijl,
the Netherlands), triacylglycerols (Roche Molecular
Biochemicals, Indianapolis, IN, USA) and Mg2+ (Roche/
Hitachi, Tokyo, Japan) concentrations were measured using
a spectrophotometric assay according to the manufacturer’s
protocols. The Mg2+ colourimetric assay was based on a
Xylidyl Blue-I method and the absorbance was measured at
600 nm. NEFAs were measured at 546 nm, triacylglycerols at
500 nm and protein at 562 nm on a Bio-Rad Benchmark plus
microplate spectrophotometer (Bio-Rad laboratories,
Hercules, CA, USA). For inductively coupled plasma mass
spectrometry (ICP-MS) analyses, serum samples were dis-
solved in HNO3 (>65%, Sigma) and diluted prior to being
subjected to ICP-MS (X-series; Thermo Scientific).
Oral lipid load in human participants As part of a study
(ClinicalTrials.gov registration no. NCT01967459), which
aimed to examine the effect of vitamin D supplementation
on postprandial leucocyte activation, 24 female volunteers
underwent an oral fat-loading test. The study was approved
by the Institutional Review Board of the Franciscus Gasthuis
& Vlietland Rotterdam and the regional independent medical
ethics committee of the Maasstad Hospital Rotterdam [34].
All participants provided informed consent. Samples from
the baseline oral fat load were used in this study to measure
serum Mg2+, NEFA and triacylglycerol concentrations.
Inclusion criteria were an age above 18 years, a premeno-
pausal status, BMI ≥25 kg/m2 and vitamin D deficiency.
Exclusion criteria were the use of any kind of medication
(except for oral contraceptives), smoking, pregnancy, partici-
pation in a clinical study less than 6 months before inclusion
and the use of vitamin supplements.
Participants visited the hospital after a 10 h overnight fast
and venous blood samples were obtained after an oral fat load
(before Vitamin D treatment). Each participant received an
oral fat load using fresh cream (Albert Heijn, Zaandam, the
Netherlands) at a dose of 50 g of fat per m2 body surface
calculated by the Mosteller formula [35]. During the oral fat
loading, test participants were not allowed to eat or to drink
(except water) and they were asked to refrain from physical
activity. Venous blood sampling was repeated at 2 h intervals
until 8 h after oral fat loading, and serum Mg2+ and NEFA
levels and plasma triacylglycerol levels were measured (as
detailed in the ‘Analytical measurements’ section above).
Two individuals were excluded due to insufficient sample
availability.
Statistical analyses Results are presented as mean ± SEM, un-
less stated otherwise. Variables of overweight individuals were
correlated univariately to serum Mg2+ levels using Pearson’s
correlation analyses (SPSS for Windows v22.0.0.1,
RRID:SCR_002865; IBM, New York, NY, USA). Based on
the initial experiment in wild-type mice, the sample size for the
experiment in Kir6.2-p.Val59Met mice was calculated using a
one-way ANOVA statistic (with Dunnett’s correction for mul-
tiple comparison); to detect an effect size of 0.3 (SD 0.13) with
a power of 80% and α level of 5%: a total of six mice were
required per group. The sample size of the oral lipid (cream)
load study in healthy individuals was assessed using a one-way
ANOVA (with Dunnett’s correction for multiple comparison);
to detect an effect size of 0.1 (SD 0.1) with a power of 80% and
an α level of 5%: a total of 23 individuals were required.
Significance ofMg2+, triacylglycerol andNEFA concentrations
at 1, 2, 4, 6 and 8 h compared with those at 0 h was evaluated
using a one-way ANOVAwith Dunnett’s correction for multi-
ple comparisons. Direct correlations between Mg2+ and triac-
ylglycerol or NEFA concentrations were assessed using linear
regression analyses. A p value of ≤0.05 was considered statis-
tically significant. All statistical analyses were performed using
Graphpad Prism v7 (RRID:SCR_002798; Graphpad software,
La Jolla, CA, USA).
Results
Serum Mg2+ levels inversely correlate with blood triacylglyc-
erol levels in overweight individuals Factors affecting blood
Mg2+ levels were evaluated in 285 overweight individuals
(BMI >27 kg/m2) from the 300-Obesity cohort (ESM
Table 1). The mean serum Mg2+ concentration in this cohort
was 0.89 ± 0.09 (SD) mmol/l, with only 2% of the individuals
having hypomagnesaemia (serum Mg2+ <0.7 mmol/l, see
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ESM Table 1 and ESM Fig. 1). Despite the fairly healthy
serum Mg2+ levels in these individuals, serum Mg2+ concen-
trations were inversely correlated with triacylglycerol levels,
predominantly those in VLDL particles (Table 1). The serum
Mg2+ concentration was also inversely correlated with
HOMA-IR. As HOMA-IR was strongly correlated with plas-
ma triacylglycerol concentration (ESM Tables 2, 3), we
questioned whether insulin resistance modulated the inverse
correlation between serum Mg2+ and plasma triacylglycerol
levels and triacylglycerols in VLDL particles. However,
HOMA-IR did not influence these correlations in multivari-
able regression analyses (ESM Tables 4 and 5).
To further investigate the relationship between lipoproteins
and serum Mg2+ level, the composition of lipoprotein particles
was investigated and the correlation of these particles with serum
Mg2+ concentration was analysed (Table 1). The concentration
of the larger VLDL particles showed the strongest inverse cor-
relations with serum Mg2+ levels (Table 1). Interestingly, the
concentration of smaller HDL particles was positively correlated
with serum Mg2+. There was no correlation between serum
Mg2+ levels and the concentration of any of the intermediate-
density lipoprotein and LDL particles (Table 1). No significant
correlation was observed between serumMg2+ and the diameter
of the VLDL, LDL or HDL particles (Table 1).
Increased triacylglycerol levels directly reduce plasma Mg2+
concentrations in mice To unravel the underlying mechanism
that explains how blood triacylglycerols are associated with
blood Mg2+ concentrations, mice were subjected to an oral
gavage of olive oil following an overnight fast. Plasma triac-
ylglycerols and NEFA levels both peaked at 4 h post-gavage
(Fig. 1a, b,Δ plasma Mg2+ −0.31 mmol/l at 4 h post-gavage).
Interestingly, the plasma Mg2+ concentration showed a recip-
rocal decrease, reaching a nadir at 4 h post-gavage (Fig. 1a, b).
At basal levels (0 h), no significant correlation was observed
between plasma Mg2+ levels and NEFA concentrations (Fig.
1c, p = 0.27). However, when plasma NEFA levels increased
(at 4 and 6 h), there was a clear inverse correlation between
plasma Mg2+ and NEFA concentrations (Fig. 1d, e, p ≤ 0.05).
When plasma NEFA levels decreased and reached a concen-
tration approaching levels at baseline (8 h), there was no lon-
ger a significant correlation between plasma NEFA and Mg2+
concentrations (Fig. 1f, p = 0.54). Similar correlations were
observed between plasma Mg2+ and triacylglycerol levels
(ESM Fig. 2a–d).
Increased blood lipids can enhance glucose-induced insulin
secretion [36]. Insulin induces a compartmental shift of Mg2+,
decreasing the blood concentration of Mg2+ and increasing
intracellular levels [37]. Hence, to rule out insulin-dependent
effects, the same oral gavage experiment was performed in
inducible Kir6.2-p.Val59Met mice, which develop
hypoinsulinaemia and hyperglycaemia [38]. In these mice, a
similar reduction in plasmaMg2+ was observed in response to
the oral gavage of olive oil as compared with wild-type mice
(Fig. 1g). However, while the reduction in the plasma Mg2+
concentration was numerically similar to that observed in
wild-type mice, it did not reach statistical significance in
Kir6.2-p.Val59Met mice due to a high variation between the
animals (which was substantially larger than in the initial ex-
periment using wild-type mice). However, a significant in-
verse correlation between plasma Mg2+ and triacylglycerols
was still observed in these hypoinsulinaemic mice (Fig. 1h,
p ≤ 0.05).
Binding of Mg2+ to albumin is NEFA-dependent As ~30% of
Mg2+ is bound to albumin, which is the predominant carrier of
NEFAs, we investigated whether the binding of Mg2+ to albu-
min is dependent on NEFAs [14]. With increasing concentra-
tions of BSA inMgCl2, we found that the Mg
2+ concentration
declined as BSA concentrations increased (Fig. 2a). Mg2+
concentrations decreased from 0.85 ± 0.02 mmol/l at
0 mmol/l BSA to 0.64 ± 0.01 mmol/l at a near-physiological
concentration of BSA (0.5 mmol/l or 33.25 g/l), a 25% reduc-
tion (Fig. 2a). Interestingly, the absence of fatty acid (i.e. the
use of FF-BSA instead of BSA in the MgCl2 solution) abro-
gated this effect, in line with the theory that binding ofMg2+ to
albumin is NEFA-dependent (Fig. 2b). Linear regression anal-
yses showed a significant inverse correlation between Mg2+
and BSA concentration (Fig. 2c); the regression constant was
approximately four times stronger for BSA than for FF-BSA
(Fig. 2c). To exclude the possibility that other cations present
in blood compete with the binding of Mg2+ to BSA, BSAwas
also dissolved in a physiological buffer, which mimicked the
concentration of other abundant blood electrolytes. This ap-
proach resulted in a similar decrease in the Mg2+ concentra-
tion with increasing BSA concentrations (Fig. 2d). Again, FF-
BSA had no significant effect on Mg2+ levels (Fig. 2e). In the
physiological buffer, BSA and FF-BSA displayed correlations
similar to those observed in the MgCl2 buffer (Fig. 2f).
NEFAs directly decrease Mg2+ concentrationsWe then set out
to modify the binding of Mg2+ to albumin by increasing the
concentration of NEFA. Elevating the concentration of
NEFAs in a BSA–MgCl2 solution directly reduced the Mg
2+
concentration (linear regression: y = −0.12x + 0.83, p ≤ 0.05;
Fig. 3a). To resemble the in vivo setting, the experiment was
repeated using FBS instead of BSA; increasing NEFA levels
in FBS reduced Mg2+ concentrations to a similar extent as
when BSA was used (linear regression: y = −0.10x + 1.36,
p ≤ 0.05; Fig. 3b). Interestingly, the NEFA-induced reduction
in Mg2+ concentration was protein-independent, as increasing
NEFA levels in a MgCl2 solution also lowered Mg
2+ concen-
tration (linear regression: y = −0.08x + 1.00, p ≤ 0.05; Fig. 3c).
Elevating triacylglycerol levels reduces serum Mg2+ concen-
tration in healthy individuals To discover whether
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Table 1 Univariate analyses for
the correlation of demographics,
laboratory measurements and li-
poprotein particle concentration
with serumMg2+ concentration in
overweight individuals from the
300-Obesity cohort
Variable Correlation coefficient p value n
Demographics
Sex (M = 0, F = 1) −0.051 0.391 285
BMI (kg/m2) −0.063 0.291 285
Age (years) −0.099 0.096 285
Waist circumference (cm) −0.071 0.231 285
SBP (mmHg) −0.016 0.791 285
DBP (mmHg) 0.079 0.186 285
Heart rate (beats/min) −0.083 0.164 282
Laboratory measures
Triacylglycerols (mmol/l) −0.159 0.007 284
Glucose (mmol/l) −0.062 0.299 284
HbA1c (mmol/mol) −0.032 0.595 284
HOMA-IR −0.123 0.038 283
Total cholesterol (mmol/l) 0.041 0.495 284
Triacylglycerols (mmol/l)
in VLDL −0.158 0.008 284
in LDL −0.026 0.667 284
in HDL −0.052 0.380 284
Cholesterol (mmol/l)
in VLDL −0.093 0.118 284
in LDL 0.075 0.205 284
HDL 0.116 0.050 284
ApoA1 (g/l) 0.071 0.235 283
ApoB (g/l) −0.037 0.539 283
Mean lipoprotein diameter (nm)
VLDL −0.095 0.111 284
LDL −0.030 0.612 284
HDL 0.026 0.320 284
Lipoprotein particle concentration (mol/l)
Chylomicrons and EL-VLDL −0.170 0.004 284
VL-VLDL −0.174 0.003 284
L-VLDL −0.163 0.006 284
M-VLDL −0.149 0.012 284
S-VLDL −0.108 0.068 284
VS-VLDL −0.004 0.942 284
IDL 0.058 0.333 284
L-LDL 0.060 0.313 284
M-LDL 0.059 0.319 284
S-LDL 0.053 0.377 284
VL-HDL 0.020 0.739 284
L-HDL 0.089 0.137 284
M-HDL 0.163 0.006 284
S-HDL 0.179 0.002 284
ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; DBP, diastolic blood pressure; EL-VLDL, extra-large
VLDL; F, female; IDL, intermediate-density lipoprotein; L-HDL, large HDL; L-LDL, large LDL; L-VLDL, large
VLDL;M,male;M-HDL,mediumHDL;M-LDL,mediumLDL;M-VLDL,mediumVLDL; SBP, systolic blood
pressure; S-HDL, small HDL; S-LDL, small LDL; S-VLDL, small VLDL; VL-HDL, very large HDL;
VL-VLDL, very large VLDL; VS-VLDL, very small VLDL
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triacylglycerols and NEFAs also affect blood Mg2+ concentra-
tion in humans, we examined samples obtained from 24 healthy
female individuals, with a BMI >25 kg/m2, who received an
oral fat load [34]. Serum NEFA and Mg2+ levels and plasma
triacylglycerol concentrations were measured over a period of
8 h. Plasma triacylglycerol levels increased significantly, from
1.18 ± 0.10 mmol/l at 0 h to a peak of 2.13 ± 0.18 mmol/l at 4 h
(Fig. 4a). Serum NEFA concentrations also significantly in-
creased, from 0.38 ± 0.03 mmol/l at 0 h to a peak of 0.76 ±
0.04 mmol/l at 6 h (Fig. 4b). In accordance with our previous
findings, serum Mg2+ levels dropped from 0.82 ± 0.01 mmol/l
at 0 h to a nadir of 0.75 ± 0.02 mmol/l at 6 h (Fig. 4a, b, Δ
plasma Mg2+ −0.07 mmol/l at 6 h post-intake). The total serum
Mg2+ concentration, as measured by ICP-MS, was not affected
by fat (cream) intake; hence, these findings suggest that only the
free Mg2+ levels were affected by lipid loading (Fig. 4c).
Discussion
Hypomagnesaemia is a common phenomenon in type 2 diabe-
tes. In the current study, we show that high blood NEFA and
triacylglycerol concentrations directly reduce blood Mg2+
levels. We also show that high NEFA levels bind Mg2+,
resulting in decreased circulating levels of free Mg2+. The con-
clusions of this study are based on complementary results from
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Fig. 1 Increased plasma NEFA
and triacylglycerol levels directly
reduce plasma Mg2+
concentration in mice. Mice were
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olive oil. (a) Plasma Mg2+ (red
circles) and triacylglycerol (blue
squares) and (b) plasma Mg2+
(red circles,) and NEFA (blue
squares) concentrations before
(0 h) and at 1, 2, 4, 6 and 8 h post-
gavage in wild-type mice (n =
12). (c–f) Linear regression
analyses of plasma Mg2+ and
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12) and 8 h (f, n = 11) post gavage
in wild-type mice, using data
from (b). Each point represents an
individual mouse; several data
points are missing due to
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(g) Plasma Mg2+ (red circles) and
triacylglycerol (blue squares)
concentrations before (0 h) and at
1, 2, 4, 6 and 8 h post-gavage in
hypoinsulinaemic Kir6.2-
p.Val59Met mice (n = 7). (h)
Linear regression analysis of
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using data shown in (g). Each
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mouse; n = 2 mice were excluded
due to insufficient sample
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SEM. *p ≤ 0.05, ***p ≤ 0.001 vs
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0.05, ††p ≤ 0.01, †††p ≤ 0.001 vs
triacylglycerol or NEFA
concentrations at 0 h.
Significance was evaluated using
a one-way ANOVAwith
Dunnett’s correction for multiple
comparisons
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in vitro studies and animal and human in vivo studies. First, in a
large cohort of overweight individuals, the concentration of
triacylglycerols in large VLDL particles was inversely correlat-
edwith serumMg2+ concentrations. Second, a dietary lipid load
directly reduced blood Mg2+ concentration in both mice and
humans, independent of insulin action. Third, in vitro, we dem-
onstrated that this phenomenon occurs due to direct binding of
NEFA molecules to Mg2+. These findings demonstrate that
triacylglycerols reduce concentrations of freeMg2+ in the blood
and consequently place hypertriacylglycerolaemic individuals
at risk for Mg2+ deficiency.
Here, we demonstrated that increased triacylglycerol and
NEFA levels reduce levels of free Mg2+(the biologically ac-
tive form of Mg2+) by a direct interaction between negatively
charged NEFA molecules and Mg2+ ions. This binding was
shown to be highly specific for Mg2+, since the presence of
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in a MgCl2 solution. The white squares indicate a BSA/FF-BSA concen-
tration (0.5 mmol/l) that is near the physiological range; all other data
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concentration in increasing levels of BSA (circles; y = −0.21x + 0.78,
r2 = 0.96, p ≤ 0.05) or FF-BSA (triangles; y = −0.05x + 0.83, r2 = 0.90,
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physiological concentrations of other cations did not affect the
interaction between Mg2+ and NEFAs. The phenomenon of
reduced Mg2+ levels as a result of elevated NEFA levels has
previously been observed in dogs, although no underlying
mechanism was suggested [39]. In addition, previous studies
have shown that Ca2+ can bind to NEFAs, and that blood Ca2+
concentrations are reduced by increasing NEFA levels in in-
dividuals [40]. However, in our in vitro experiments, the ad-
dition of physiological concentrations of Ca2+ did not affect
the Mg2+–NEFA interaction, indicating a higher affinity of
Mg2+ compared with Ca2+ for binding to NEFAs. This is
likely due to the fact that the Mg2+ ion has a significantly
higher charge density than the Ca2+ ion [41].
The findings from this studymay explain why certain factors
that affect circulating NEFAs are associated with changes in
blood Mg2+ concentrations. For example, molecules such as
β-adrenergic agonists, ethanol and adrenaline (epinephrine),
which activate lipolysis and, hence, increase blood NEFA
levels, are associated with reduced blood Mg2+ levels [1,
42–44]. Indeed, an intravenous infusion of the β-adrenergic
agonist terbutaline causes a reduction in serum Mg2+ concen-
tration, which is correlated to the elevated concentrations of
plasma NEFAs, but not glucose [45]. Although, this does not
exclude the possibility of additional potential mechanisms for
Mg2+ decrease with use of these agents. In addition, prolonged
fasting, which induces lipolysis and increases circulating
NEFAs, also results in hypomagnesaemia [46].
Approximately 30% of blood Mg2+ is bound to albumin
[14]. However, our data indicate that the binding of Mg2+ to
albumin depends on the availability of NEFA. Our findings
suggest that direct binding of Mg2+ to albumin is minimal,
since NEFA-depleted albumin showed little binding to Mg2+.
To correct for albumin binding, a factor of 0.7 is used when
calculating the fractional excretion of Mg2+(FEMg):
FEMg = [(uMg × sCr)/(sMg × uCr × 0.7)] × 100), where sMg
and uMg are the serum and urinary Mg2+ levels, respectively,
and sCr and uCr are the serum and urinary creatinine levels,
respectively [47]. As the large majority of NEFAs in blood are
bound to albumin, alterations in NEFA concentrations may be
the determining factor in the binding of Mg2+ to albumin [22].
This paradigm change questions the current protocol for calcu-
lating FEMg. The use of the factor of ‘0.7’ is accurate in phys-
iological conditions but will lead to inaccurate calculations in
pathological conditions such as hypertriacylglycerolaemia.
Several limitations need to be considered with regard to this
study. Hypertriacylglycerolaemia in mice was achieved using
oliveoil,while inhumanvolunteers thiswasdonebyanoral load
of cream.Oliveoil containsnoMg2+,while the creamused in the
human study contains 3.3 mmol/l Mg2+, leading to a potential
underestimation of the reduction in serum Mg2+ in the healthy
volunteers. Moreover, in the in vitro experiments, NEFAs
extracted fromBSAwereused to increaseNEFAlevels in several
solutions. However, the yield of this extraction procedure was
not equal in each experiment performed, making it difficult to
combine data from all experiments. Despite these differences in
NEFAyield, the results were similar in all four replicate experi-
ments. Finally, in overweight individuals and in individualswith
type 2 diabetes, Mg2+ inversely correlates with triacylglycerols
[1, 23, 24]. Our in vitro data show direct binding of Mg2+ to
NEFA molecules, which, in contrast to triacylglycerol mole-
cules, possess a negative charge. It is unlikely that Mg2+ binds
to uncharged triacylglycerol molecules. However, in humans,
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Fig. 4 Increased serum NEFA and plasma triacylglycerol levels directly
reduce serum Mg2+ concentrations in healthy overweight or obese wom-
en. Female volunteers underwent an oral fat (cream) loading test. (a)
Serum Mg2+ (red circles) and plasma triacylglycerol (blue squares) and
(b) serum Mg2+ (red circles) and NEFA (blue squares) concentrations
before (0 h) and at 1, 2, 4, 6 and 8 h after an oral lipid load in healthy
overweight women (n = 22). (c) Total serum Mg2+ levels measured by
ICP-MS before (0 h) and 4 and 8 h after oral lipid intake. Data are mean ±
SEM.*p ≤ 0.05 vs Mg2+ concentrations at 0 h; †p ≤ 0.05, ††p ≤ 0.01,
†††p ≤ 0.001 vs triacylglycerol or NEFA concentrations at 0 h.
Significance was evaluated using a one-way ANOVA with Dunnett’s
correction for multiple comparisons
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blood triacylglycerols and NEFA levels strongly correlate,
meaning that most individuals with hypertriacylglycerolaemia
also have elevated NEFA levels, which would underlie the
inverse correlation betweenMg2+ and triacylglycerols [48–51].
This study has several strengths. Our data extend from mol-
ecule to population and have clinical implications. Moreover,
we demonstrated the directionality of the inverse association
between triacylglycerols and Mg2+, which could explain why
hypomagnesaemia is so prominent in diseases such as type 2
diabetes. Our data do not rule out the possibility that changes in
Mg2+ concentrations could also influence lipid levels.
In conclusion, we show that elevated blood NEFA and
triacylglycerol levels directly reduce blood Mg2+ concentra-
tions by the binding of Mg2+ ions to NEFA molecules. Our
data explain the high prevalence of hypomagnesaemia in sev-
eral metabolic diseases, characterised by elevated triacylglyc-
erol levels [1–3]. In individuals with these diseases, those with
hypertriacylglycerolaemia are at particular risk for
hypomagnesaemia, and therefore, blood Mg2+ levels should
be routinely measured and monitored.
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